MyFinsight
Home
Blog
About
Contact
Download
Download image
It represents the
proceeds from issuance of...
$11,000K
Represents proceeds from
issuance of ordinary...
$5,036K
Proceeds from warrant
exercises
$2,644K
Net cash provided by
(used in) financing...
$15,640K
Canceled cashflow
$3,040K
Cash, cash
equivalent, restricted...
$4,807K
Canceled cashflow
$10,833K
Proceeds from issuance
initial public offering
-$1,530K
Issuance costs related to
warrants inducement...
$740K
Represent the value of
payment of underwriters...
$696K
Represents the amount of
prepaid of issuance cost...
$74K
Decrease (increase) in
prepaid expenses
-$396K
Other non-cash
financial expenses...
-$344K
Increase (decrease) in
employee related...
$237K
Share-based payment
arrangement, noncash expense
$134K
Increase (decrease) in
accrued liabilities
$102K
Depreciation
$14K
Decrease (increase) in
other current assets
-$13K
Net cash provided by
(used in) operating...
-$10,819K
Net cash provided by
(used in) investing...
-$14K
Canceled cashflow
$1,240K
Net loss
-$11,912K
Purchase of property and
equipment
$9K
Investment in long-term
deposits
$5K
Increase (decrease) in
accounts payable, trade
-$142K
Increase (decrease) in
operating lease liability
-$5K
Back
Back
Cash Flow
source: myfinsight.com
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)